Abstract 116P
Background
Lung adenocarcinoma (LUAD) is the most prevalent subtype of non-small cell lung cancer. The prognostic role of Fibrous sheath interacting protein 1 (FSIP1) in LUAD remains unclear. Thus, this study aims to identify and validate the prognostic value of FSIP1 in LUAD and explore its molecular functions.
Methods
Single-cell RNA sequencing (scRNA-seq) data of LUAD patients were collected from Gene Expression Omnibus (GEO) database, the major cell types were identified based on known markers. Additionally, the expression of FSIP1 was detected in 180 LUAD samples, Kaplan-Meier (KM) analysis of high- and low-expression patients was conducted. Univariate and multivariate Cox regression analyses were utilized to assess the prognostic ability of FSIP1. Then, FSIP1-silenced human LUAD cell lines were constructed, and the functions of FSIP1 were explored. Finally, immune infiltration analysis was performed in LUAD patients.
Results
In this study, we identified LUAD FSIP1+ cancer cells by using scRNA-seq data from GEO database. Additionally, we investigated the protein level and prognostic value of FSIP1 in 98 LUAD patients using Tissue Microarray. Compared with the adjacent, FSIP1 was higher expressed in LUAD tissues. KM analysis revealed that the 5-year OS rate to be 30% to 59% (FSIP1High vs FSIP1Low) in Tissue Microarray. Univariate and multivariate COX regression showed that FSIP1 should be an independent factor in poor prognosis. The receiver operating characteristic curve (ROC) and time-ROC curve both indicated that FSIP1 had a good performance in prognostic model. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis showed that FSIP1 was associated with migration. Migration assay and Western blotting showed that FSIP1 influenced cell migration and PI3K/AKT pathway. FSIP1 could influence the immune cell infiltration in lung adenocarcinoma patients.
Conclusions
This study verified that FSIP1 could serve as a valuable prognostic biomarker in LUAD and analyzed its impact on the disease and its association with the immune infiltration. The findings of this research provide valuable insights into the understanding of LUAD and could potentially lead to the development of new treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
112P - Reporting of molecular test results from cell-free DNA analyses: Expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA workshop
Presenter: Vincent de Jager
Session: Poster session 08
114P - Prevalence and landscape of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma
Presenter: Oscar Gerardo Arrieta Rodriguez
Session: Poster session 08
115P - Gene rearrangements, actionability and access to precision medicine: Results from the ARCAGEN study
Presenter: Marie Morfouace
Session: Poster session 08
117P - Methylome and transcriptome profiling of hepatoid adenocarcinoma of the stomach
Presenter: Shirong Zhang
Session: Poster session 08
Resources:
Abstract
118P - Comparative analysis of DNA and RNA-based NGS for detecting MET exon 14 skipping mutation in pan-solid tumor samples
Presenter: Ruijun Cai
Session: Poster session 08
119P - Predicting the pathogenicity of novel fusion genes and explaining reasons using a large language model: A focused assessment
Presenter: Katsuhiko Murakami
Session: Poster session 08
120P - A prospective comparative evaluation of automatic trial match tools in a molecular tumor board
Presenter: Lilia GUEGUEN
Session: Poster session 08
122P - Practice patterns and treatment outcomes of molecular tumour board (MTB)-based personalized cancer therapies: A single-center experience
Presenter: Florian Moik
Session: Poster session 08